Compare CVS Health Corp (CVS) vs Las Vegas Sands Corp. (LVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CVS Health Corp vs Las Vegas Sands Corp. — how do they compare? CVS Health Corp trades at $93.7 (market cap $122.36B), while Las Vegas Sands Corp. trades at $45.98 (market cap $29.44B). The key difference: CVS Health Corp is far larger — about 4.2× Las Vegas Sands Corp.'s market cap, and CVS Health Corp pays the higher dividend (2.78%). Which is the better fit depends on your goals.
| CVS | LVS | |
|---|---|---|
Market Cap | $122.36B | $29.44B |
Sector | Health | Consumer Cyclical |
52-Week High | $110.60 | $69.49 |
52-Week Low | $65.51 | $44.78 |
Enterprise Value | $184.71B | $41.33B |
Dividend Yield | 2.78% | 2.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $95.70, down 0.54% on the day, with a bearish technical signal and key support at $95. The company reported strong Q2 2026 earnings, beating estimates with EPS of $2.58 versus $1.87 expected, and raised its full-year guidance. Revenue growth remains robust, reaching $402.07 billion in 2025, though net income margin compressed to 1.18%. Analyst sentiment is overwhelmingly positive with a consensus price target of $115.00.
The outlook for CVS is cautiously optimistic, driven by operational improvements in its Aetna segment and raised cash flow guidance. Investment opportunities include potential upside to the consensus target, but risks involve margin pressures, regulatory changes impacting pharmacy benefits in 2027, and high debt levels. The stock's current valuation at a P/E of 25.25 may limit near-term gains if earnings growth slows.
LVS trades at $45.77, down 0.74% on the day, with a bearish technical signal and recent Q2 2026 earnings miss. The company shows strong fundamentals with revenue growth to $13.02B in 2025, a net income margin of 12.59%, and robust cash flow from operations of $3.02B. Analyst consensus remains bullish with a $60.75 price target and 59% buy ratings, supported by positive corporate news on ESG achievements and community initiatives.
The outlook for LVS is mixed; strong profitability and analyst optimism contrast with technical bearishness and high debt levels. Upside potential exists if earnings rebound, but risks include competitive pressures and macroeconomic sensitivity. The stock's current valuation at a P/E of 17.74 offers a reasonable entry if operational execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CVS Health Corp
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →About Las Vegas Sands Corp.
Las Vegas Sands is the world's largest operator of fully integrated resorts, featuring casino, hotel, entertainment, food and beverage, retail, and convention center operations. The company owns the Venetian Macao, Sands Macao, Londoner, Four Seasons Hotel Macao, and Parisian in Macao, and the Marina Bay Sands resort in Singapore. Its Venetian and Palazzo Las Vegas in the U.S. asets were sold to Apollo and VICI for $6.25 billion in 2022. We expect Sands to open a fourth tower in Singapore in 2026. After the sale of its Vegas assets, the company will generate all its EBITDA from Asia, with its casino operations generating the majority of sales.
Read more on LVS →
